Related Experiment Video
Updated: Jan 8, 2026
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Serum interferon gamma-induced protein 10 in obese non-diabetic patients with metabolic dysfunction-associated
Mohamed Fouad1, Olfat Fawzy1, Sally Abd El-Aziz1
1Department of Endocrinology and Metabolism, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Introduction:
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most prevalent chronic liver disease globally, strongly linked to obesity, insulin resistance, and metabolic syndrome. Inflammation plays a central role in MASLD progression, with interferon gamma-induced protein 10 (IP-10/CXCL10) emerging as a key chemokine implicated in immune cell recruitment, hepatic injury, and fibrosis. However, its level in obese non-diabetic MASLD patients remains underexplored. This study aimed to evaluate serum IP-10 levels in obese, non-diabetic MASLD patients and explore their association with anthropometric, metabolic, and hepatic parameters.
Patients And Methods:
We conducted a case-control study, including 120 participants, divided into 60 obese non-diabetic MASLD patients (diagnosed clinically and radiologically) and 60 age- and sex-matched healthy controls. Serum IP-10 was measured by ELISA. Correlations with anthropometric indices, biochemical markers, insulin resistance, and hepatic steatosis (HSI) and fibrosis stiffness (FIB-4) scores were analysed. Diagnostic accuracy of IP-10 was assessed using ROC curve analysis.
Results:
Serum IP-10 levels were significantly higher in MASLD patients compared to controls. IP-10 correlated positively with BMI, waist circumference, ALT, AST, fasting insulin, HOMA-IR, and hepatic steatosis stage, and negatively with HDL-C. ROC analysis showed that an IP-10 cutoff > 830.1 pg/mL discriminated obese MASLD with an AUC of 0.805, sensitivity of 61.7%, and specificity of 86.7%.
Conclusion:
Serum IP-10 is significantly elevated in obese non-diabetic MASLD patients and strongly associated with metabolic derangements, insulin resistance, and hepatic steatosis. These findings suggest that IP-10 may serve as a promising early non-invasive risk stratification tool or an adjunctive biomarker for MASLD.
